Assay of tetramisole in immune-depressed mice

A. Sassen; F. Vander Plaetse; M. Janowski

doi:10.1007/BF00200070

Assay of tetramisole in immune-depressed mice

A. Sassen, F. Vander Plaetse, M. Janowski

Research output › peer-review

Abstract

Mice injected with a Radiation Leukemia Virus, vaccinated against the Rauscher leukemia, or irradiated under various conditions, were subjected to Tetramisole treatment in order to demonstrate an eventual increase of their immunological potential. Doses between 0.4-250 μg per injection, and various routes and timing of administration were tested. In order to assess various parameters of the immune system, the following factors were taken into consideration: survival, spleen weight, immunoglobulin level, humoral immune response, antibodies against viral glycoprotein, leukocyte migration test and phagocytosis. The results obtained with these tests did not demonstrate a definite adjuvant effect of Tetramisole.

Original language	English
Pages (from-to)	125-130
Number of pages	6
Journal	Cancer Immunology Immunotherapy
Volume	3
Issue number	2
DOIs	https://doi.org/10.1007/BF00200070
State	Published - Dec 1977

ASJC Scopus subject areas

Immunology and Allergy
Immunology
Oncology
Cancer Research

Access to Document

10.1007/BF00200070

Cite this

@article{888e450f57cb4961972512ccce4a7a45,

title = "Assay of tetramisole in immune-depressed mice",

abstract = "Mice injected with a Radiation Leukemia Virus, vaccinated against the Rauscher leukemia, or irradiated under various conditions, were subjected to Tetramisole treatment in order to demonstrate an eventual increase of their immunological potential. Doses between 0.4-250 μg per injection, and various routes and timing of administration were tested. In order to assess various parameters of the immune system, the following factors were taken into consideration: survival, spleen weight, immunoglobulin level, humoral immune response, antibodies against viral glycoprotein, leukocyte migration test and phagocytosis. The results obtained with these tests did not demonstrate a definite adjuvant effect of Tetramisole.",

author = "A. Sassen and Plaetse, {F. Vander} and M. Janowski",

year = "1977",

month = dec,

doi = "10.1007/BF00200070",

language = "English",

volume = "3",

pages = "125--130",

journal = "Cancer Immunology Immunotherapy",

issn = "0340-7004",

publisher = "Springer Verlag",

number = "2",

}

TY - JOUR

T1 - Assay of tetramisole in immune-depressed mice

AU - Sassen, A.

AU - Plaetse, F. Vander

AU - Janowski, M.

PY - 1977/12

Y1 - 1977/12

N2 - Mice injected with a Radiation Leukemia Virus, vaccinated against the Rauscher leukemia, or irradiated under various conditions, were subjected to Tetramisole treatment in order to demonstrate an eventual increase of their immunological potential. Doses between 0.4-250 μg per injection, and various routes and timing of administration were tested. In order to assess various parameters of the immune system, the following factors were taken into consideration: survival, spleen weight, immunoglobulin level, humoral immune response, antibodies against viral glycoprotein, leukocyte migration test and phagocytosis. The results obtained with these tests did not demonstrate a definite adjuvant effect of Tetramisole.

AB - Mice injected with a Radiation Leukemia Virus, vaccinated against the Rauscher leukemia, or irradiated under various conditions, were subjected to Tetramisole treatment in order to demonstrate an eventual increase of their immunological potential. Doses between 0.4-250 μg per injection, and various routes and timing of administration were tested. In order to assess various parameters of the immune system, the following factors were taken into consideration: survival, spleen weight, immunoglobulin level, humoral immune response, antibodies against viral glycoprotein, leukocyte migration test and phagocytosis. The results obtained with these tests did not demonstrate a definite adjuvant effect of Tetramisole.

UR - http://www.scopus.com/inward/record.url?scp=0017592631&partnerID=8YFLogxK

U2 - 10.1007/BF00200070

DO - 10.1007/BF00200070

M3 - Article

AN - SCOPUS:0017592631

SN - 0340-7004

VL - 3

SP - 125

EP - 130

JO - Cancer Immunology Immunotherapy

JF - Cancer Immunology Immunotherapy

IS - 2

ER -